

1 RESEARCH ARTICLE

2

3 **Effect of continuous compressive force on the expression of RANKL,**  
4 **OPG, and VEGF in MC3T3-E1 and MLO-Y4 cells**

5

6 Yuka Yashima<sup>1¶</sup>, Masato Kaku<sup>1\*</sup>, Taeko Yamamoto<sup>1&</sup>, Jin Izumino<sup>1&</sup>, Haruka  
7 Kagawa<sup>1&</sup>, Kotaro Tanimoto<sup>1¶</sup>

8

9 <sup>1</sup>Department of Orthodontics and Craniofacial Developmental Biology, Hiroshima  
10 University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku,  
11 Hiroshima 734-8553, Japan

12

13 Corresponding author

14

15 E-mail: [mkaku@hiroshima-u.ac.jp](mailto:mkaku@hiroshima-u.ac.jp)

16

17

18 <sup>¶</sup>These authors contributed equally to this work.

19 <sup>&</sup> These authors also contributed equally to this work.

20

21

22

23

24 **Abstract**

25 Osteocytes, known to have mechano-sensory functions, influence the regulation of

26 bone remodeling. However, the mechanism by which osteocytes regulate bone

27 metabolism when mechanical forces are being applied is still unclear.

28 Osteoclastogenesis is mainly regulated by receptor activator of nuclear factor kappa-B

29 ligand (RANKL); the protein osteoprotegerin (OPG) and angiogenesis also play  
30 important roles in osteogenesis. RANKL, OPG, and vascular endothelial growth factor  
31 (VEGF) are thought to be key factors for bone metabolism. In this study, we examined  
32 the effect of a continuous compressive force (CF) on the expression of RANKL, OPG,  
33 and VEGF in osteoblastic murine osteocytes (MLO-Y4) and osteoblastic (MC3T3-E1)  
34 cells. Gene and protein expression levels of RANKL, OPG, and VEGF in MLO-Y4 and  
35 MC3T3-E1 cells were quantitatively determined by real-time PCR and enzyme-linked  
36 immunosorbent assay (ELISA). Both cell types were also subjected to a CF of 1.0 g/cm<sup>2</sup>  
37 for 1, 3, 6, and 12 hours. Furthermore, the effect of a stretch-activated (S-A) channel  
38 was examined by gadolinium (Gd<sup>3+</sup>) administration. The ratio of gene and protein  
39 expressions of RANKL, VEGF, and RANKL/OPG in MLO-Y4 cells were significantly  
40 higher than in MC3T3-E1 cells, while the expression of OPG was significantly lower.  
41 After CF application, both cell types showed significant increases in RANKL and  
42 VEGF expression as well as the RANKL/OPG ratio. Additionally, the upregulated gene  
43 and protein levels of these factors were reduced by Gd<sup>3+</sup> administration.  
44 These findings suggest that osteocytes play more important roles in bone metabolism

45 and angiogenesis than osteoblasts. Osteocytes regulate the expression of RANKL, OPG,  
46 and VEGF via the S-A channel through the response to mechanical stress.

47

## 48 **Introduction**

49 Bone tissue shows constant remodeling by osteoblastic bone formation and  
50 osteoclastic bone resorption in order to maintain bone volume and homeostasis [1, 2].  
51 Therefore, bone remodeling has been suggested to be regulated by a crosstalk between  
52 osteoblasts, osteoclasts, and osteocytes [3]. Receptor activator of nuclear factor kappa-B  
53 ligand (RANKL) [4] and osteoprotegerin (OPG) [5] are crucial factors for osteoclast  
54 differentiation. Osteoblasts have been thought to be the main source of RANKL for  
55 osteoclastogenesis [6, 7], and therefore investigations of RANKL expression and their  
56 mechanism have been mostly studied in osteoblastic cells [8, 9]. Vascular endothelial  
57 growth factor (VEGF), which is a mitogen specific for vascular endothelial cells, plays  
58 a major role in angiogenesis [10]. As bone tissue is rich in blood vessels, and bone  
59 remodeling requires neovascularization, VEGF is thought to be an important factor not

60 only for angiogenesis but also for skeletal development and bone regeneration [11].

61 It is well known that mechanical stress can influence the regulation of bone  
62 remodeling. Nettelhoff et al. reported that the highest RANKL/OPG ratio was observed  
63 after the application of 5% compressive force (CF) in osteoblasts [12]. Tripuwabhrut et  
64 al. also suggested that CFs on osteoblasts enhance osteoclastogenesis by an increase in  
65 RANKL expression and decrease in OPG expression [13]. It has been reported that  
66 cyclic tensile forces increase the mRNA and protein expressions of VEGF in  
67 osteoblastic MC3T3-E1 cells [14], and this reaction was inhibited by gadolinium  
68 ( $Gd^{3+}$ ), a stretch-activated (S-A) channel blocker [15]. Reher et al. showed that the  
69 production of VEGF in human osteoblasts can be increased by ultrasounds at 1 MHz  
70 and 45 kHz [16]. These results suggest that the application of mechanical stress on  
71 osteoblasts can affect the expressions of RANKL, OPG, and VEGF, thereby  
72 accelerating bone remodeling.

73 Osteocytes, which account for more than 90% of the cells in bone tissue, are derived  
74 from osteoblasts and are embedded in the bone matrix and function as mechanosensory

75 cells through the lacuno-canalicular network [17]. Recently, it was shown that  
76 osteocytes can be a main source of RANKL during bone remodeling [18, 19]. However,  
77 the effects of mechanical forces on the expression of factors related to bone remodeling  
78 between osteocytes and osteoblasts are still unclear. In this study, we examined the  
79 effects of CF on the expression of RANKL, OPG, and VEGF in murine osteocytes  
80 (MLO-Y4) and compared to that in osteoblastic (MC3T3-E1) cells. We also  
81 investigated the influence of  $Gd^{3+}$ , which blocks the S-A channel upon the expression of  
82 RANKL, OPG, and VEGF.

83

## 84 **Materials and methods**

85

### 86 **Cell culture**

87 Murine osteoblastic MC3T3-E1 cells were obtained from RIKEN Cell Bank (Tsukuba,  
88 Japan), and cultured in alpha minimum essential medium ( $\alpha$ -MEM) supplemented with  
89 10% FBS. All cell lines were cultured with 240 ng/mL kanamycin (Meiji Seika, Tokyo,  
90 Japan), 1 mg/mL amphotericin-B (ICN Biomedicals Corp, Costa Mesa, CA, USA), 500

91 ng/mL penicillin (Sigma Aldrich, Saint Louis, MO, USA) at 37°C in 5% CO<sub>2</sub>. Murine  
92 osteocyte-like cells (MLO-Y4 cells) were obtained from Kerfast (Boston, MA, USA),  
93 and cultured on collagen-coated plates (pig tendon type I collagen, IWAKI, Tokyo,  
94 Japan) in  $\alpha$ -MEM (Sigma Aldrich, Saint Louis, MO, USA) with 2.5% heat inactivated  
95 fetal bovine serum (FBS, Daiichi Chemical, Tokyo, Japan) and 2.5% heat inactivated  
96 newborn calf serum (CS, Thermo Fisher Scientific, Waltham, MO, USA). The medium  
97 was changed twice a week, and cells were subcultured by treatment with 0.05% trypsin  
98 and 0.53 mM ethylenediaminetetraacetic acid (EDTA) followed by plating at a density  
99 of  $5 \times 10^4$  cells/well in 6-well plates. For all experiments, cells between the 4th and the  
100 6th passages were used.

101

## 102 **Application of CF**

103 MC3T3-E1 and MLO-Y4 cells were continuously compressed by a uniform  
104 compression method with serum-free conditioned media in 6-well plates at a density of  
105 50,000 cells according to the previous study by Tripuwabhrut et al. (Fig. 1) [20]. A thin  
106 glass plate was placed over a confluent cell layer, and the cells were subjected a CF of

107 1.0 g / cm<sup>2</sup> for various loading time (1, 3, 6, and 12 hours) to examine the expressions  
108 of RANKL, OPG, VEGF, and RANKL/OPG ratio.

109

110 **Fig 1.**

111 A schematic drawing of compression force application (CF) on the cell layer. 1.0 g /  
112 cm<sup>2</sup> weight is placed over a confluent cell layer.

113

#### 114 **Total RNA extraction and cDNA synthesis**

115 Total RNA was isolated from the cell cultures with or without the application of CF  
116 using a Quickprep Total RNA extraction kit (Amersham Biosciences, Tokyo, Japan).

117 Single-stranded cDNA was synthesized from 1 µg of total RNA using Oligo (dT)<sub>20</sub>

118 primer (Toyobo, Osaka, Japan) and a Rever Tra Ace-α first-strand cDNA synthesis kit  
119 (Toyobo).

120

#### 121 **Primers**

122 RANKL: 5'- CATCGCTCTGTTCCCTGTACTTTC -3' (forward),

123 5'- AGGAGTCAGGTAGTGTGTCTTCA -3' (reverse);

124 OPG: 5'- ACCCAGAAACTGGTCATCAGC -3' (forward),

125 5'- CTGCAATACACACTCATCACT -3' (reverse);

126 VEGF: 5'- ATGCGGATCAAACCTCA -3' (forward),

127 5'- TTCTGGCTTTGTTCTGTCTT -3' (reverse);

128 glyceraldehyde-3-phosphate dehydrogenase (G3PDH) primers (Rever Tra Ace- $\alpha$ ,

129 First-strand cDNA Synthesis Kit, Toyobo) was used as a control primer:

130 5'- ATGGCCTTCCGTGTTTCCT -3' (forward),

131 5'- CCCAAGATGCCCTTCAGT -3' (reverse).

132

## 133 **Quantitative real-time polymerase chain reaction (PCR)**

### 134 **analysis**

135 Quantitative real-time PCR was carried out using the SYBR Green I assay in

136 conjunction with an ABI Prism 7700 sequence detection system (Biosystems, Foster

137 City, CA, USA). A template cDNA at a volume of 1  $\mu$ L was used during the PCR under

138 the following parameters: 2 min at 50°C; 10 min at 95°C; and then 40 cycles of 45 sec



139 at 94°C, 45 sec at 55°C, and 45 sec at 72°C. SYBER Green I dye intercalation into the  
140 minor groove of double-stranded DNA reached maximum emission at 530 nm. PCR  
141 reactions for each sample were repeated three times for both the target gene and the  
142 control. Quantitative results of real-time fluorescence PCR were assessed by a cycle  
143 threshold (Ct) value, which identifies a cycle when the fluorescence of a given sample  
144 becomes significantly different from the baseline signal. Relative quantifications of the  
145 RANKL, OPG, and VEGF signals were normalized and expressed relative to the  
146 G3PDH signals.

147

## 148 **Measurement of protein concentrations of RANKL, OPG,** 149 **VEGF, and RANKL/OPG ratio**

150 The culture medium with or without the application of CF was collected and cleared at  
151 3000 rpm for 5 minutes for enzyme-linked immunosorbent assay (ELISA). The amount  
152 of protein concentration of RANKL (Murine sRANK Ligand Mini ABTS ELISA  
153 Development kit, PeproTech Inc, Rocky Hill, NJ, USA), OPG (Osteoprotegerin Mouse  
154 Immunoassay kit, R&D Systems, Minneapolis, MN, USA), and VEGF (Murine VEGF

155 Mini ABTS ELISA Development kit, PeproTech Inc, Rocky Hill, NJ, USA) were  
156 measured using the quantitative sandwich enzyme immunoassay technique according to  
157 the manufacturer's instructions. Standard curves were obtained as usual, and the  
158 experiment was repeated three times.

159

160 **Effects of Gadolinium ( $Gd^{3+}$ ) on the expressions of RANKL,**  
161 **OPG, and VEGF as well as the RANKL/OPG ratio in**  
162 **MLO-Y4 cells**

163 The effects of  $Gd^{3+}$  on the expression of RANKL, OPG, and VEGF in MLO-Y4 cells  
164 were examined under CF group. Because it has been reported that 1–100  $\mu M$   
165 gadolinium inhibited S-A channels [21], cells were incubated with 10  $\mu M$   $Gd^{3+}$  chloride  
166 hexahydrate (Wako, Osaka, Japan) for 30 min. After treatment of  $Gd^{3+}$ , 1.0 g/cm<sup>2</sup> CF  
167 was applied for 3 hours to assess the effects of CF on the expressions of RANKL, OPG,  
168 VEGF mRNAs and RANKL/OPG ratio. Furthermore, 1.0 g/cm<sup>2</sup> CF was also applied  
169 for 12 hours to examine the amounts of RANKL, OPG, VEGF proteins and  
170 RANKL/OPG ratio.

171

## 172 **Statistical treatment**

173 The Student's *t*-test was used to evaluate statistical differences in RANKL, OPG, and  
174 VEGF mRNA and protein expressions as well as the RANKL/OPG ratio between the  
175 MLO-Y4 and MC3T3-E1 cells. Statistical significances in mRNA and protein levels  
176 after the application of CF was assessed by analysis of variance followed by the  
177 Fisher's method. A  $p < 0.05$  was considered statistically significant.

178

## 179 **Results**

180

### 181 **Expression of mRNA and protein concentrations of RANKL,** 182 **OPG, VEGF, and RANKL/OPG ratio in MT3T3-E1 and** 183 **MLO-Y4 cells**

184 RANKL and VEGF mRNA expressions and the RANKL/OPG ratio in MLO-Y4 cells  
185 were significantly higher than that in MC3T3-E1 cells (Figs. 2A, 2C, and 2D). The gene  
186 expression level of OPG was significantly lower in MLO-Y4 cells than that in

187 MC3T3-E1 cells (Fig. 2B).

188 Similarly, MLO-Y4 cells had a significantly lower level of OPG secretion (Fig. 2F),

189 but higher levels of RANKL and VEGF secretions as well as a higher RANKL/OPG

190 ratio (Figs. 2E, 2G, and 2H) compared with MC3T3-E1 cells.

191

192 **Figs 2.**

193 Comparison in the gene expression of RANKL (A), OPG (B), VEGF (C) and RANKL /

194 OPG ratio (D), and the protein concentration of RANKL (E), OPG (F), VEGF (G) and

195 RANKL / OPG ratio (H) between MC3T3-E1 and MLO-Y4 cells. (\*\*; P<0.01)

196

197 **Time-course effects of 1.0 g/cm<sup>2</sup> CF on the expressions of**

198 **RANKL, OPG, and VEGF as well as the RANKL/OPG ratio**

199 MC3T3-E1 and MLO-Y4 cells were cultured with or without 1.0 g/cm<sup>2</sup> CF for up to

200 12 hours. RANKL gene expression and the RANKL/OPG ratio reached maximum

201 levels after 3 hours of CF application in both MC3T3-E1 and MLO-Y4 cells (Figs. 3A,

202 3D, 3E, and 3H). VEGF mRNA levels in MLO-Y4 cells were maximum 3 hours after

203 CF application (Fig 3G). Protein levels of RANKL and VEGF in MC3T3-E1 cells of  
204 the CF group were significantly higher than that of the control group at 3, 6, and 12  
205 hours (Fig 4A); and 6 and 12 hours; respectively (Fig 4C). Protein levels of RANKL  
206 and VEGF in MLO-Y4 cells of the CF group were significantly higher than that of the  
207 control group at 6 and 12 hours (Fig 4E); and 1, 3, and 12 hours; respectively (Fig 4G).  
208 Both MC3T3-E1 and MLO-Y4 cells showed a significant increase in the RANKL/OPG  
209 ratio at 3, 6, and 12 hours (Figs 4D and 4H).

210

### 211 **Figs 3.**

212 Changes in the gene expression of RANKL (A), OPG (B), VEGF (C) and RANKL /  
213 OPG ratio (D) in MC3T3-E1 cells and RANKL (E), OPG (F), VEGF (G) and RANKL /  
214 OPG ratio (H) in MLO-Y4 cells after 1, 3, 6 and 12 hours CF application of 1.0 g / cm<sup>2</sup>.  
215 (\*; P<0.05 and \*\*; P<0.01 respectively)

216

### 217 **Figs 4.**

218 Protein concentration of RANKL (A), OPG (B), VEGF (C) and RANKL / OPG ratio

219 (D) in MC3T3-E1 cells and RANKL (E), OPG (F), VEGF (G) and RANKL / OPG ratio  
220 (H) in MLO-Y4 cells after 1, 3, 6 and 12 hours CF application of 1.0 g / cm<sup>2</sup>. (\*; P<0.05  
221 and \*\*: P<0.01 respectively)

222

### 223 **Effect of Gd<sup>3+</sup> Treatment in MLO-Y4 cells**

224 In MLO-Y4 cells, RANKL gene expression and the RANKL/OPG ratio in the CF  
225 group were significantly reduced by treatment with 10 μM Gd<sup>3+</sup> (Figs 5A and 5D).  
226 Protein levels of RANKL and VEGF as well as the RANKL/OPG ratio were  
227 significantly lower in the Gd<sup>3+</sup> treatment group than in the non-treatment group (Figs  
228 6A, 6C, and 6D).

229

### 230 **Figs 5.**

231 Effects of Gd<sup>3+</sup> on the gene expression of RANKL (A), OPG (B), VEGF (C) and  
232 RANKL / OPG ratio (D) after 1.0 g / cm<sup>2</sup> CF application in MLO-Y4 cells. (\*; P<0.05  
233 and \*\*: P<0.01 respectively)

234

235 **Figs 6.**

236 Effects of  $Gd^{3+}$  on the protein concentration of RANKL (A), OPG (B), VEGF (C) and  
237 RANKL / OPG ratio (D) after 1.0 g / cm<sup>2</sup> CF application in MLO-Y4 cells. (\*; P<0.05  
238 and \*\*; P<0.01 respectively)

239

240 **Discussion**

241 Osteoblasts have been considered a main source of RANKL and OPG, which play  
242 essential roles in osteoclastogenesis [6, 7]. However, recent studies have demonstrated  
243 that osteocytes mainly regulate physiological osteoclastogenesis by the production of  
244 RANKL during bone remodeling [18, 19]. In this study, the mRNA and protein  
245 expression levels of RANKL as well as the RANKL/OPG ratio in MLO-Y4 cells were  
246 significantly higher than in MC3T3-E1 cells, which is in accordance with results from  
247 previous studies [18, 19]. Furthermore, the gene and protein expression levels of OPG  
248 were significantly lower in MLO-Y4 cells than in MC3T3-E1 cells. These results  
249 suggested that osteocytes play a more important role for osteoclastogenesis by  
250 enhancing RANKL expression and suppressing OPG expression compared to

251 osteoblasts.

252 Osteocytes are differentiated from osteoblasts, which are embedded in the bone matrix

253 with extended dendritic processes. For crosstalk among the bone component cells,

254 dendritic processes are thought to be essential because osteocytes connect each other

255 and adjacent cells [17]. Although the importance of cellular reaction for bone

256 remodeling is well known, the mechanism that osteocytes use to promote cytokines for

257 bone remodeling after receiving mechanical stress, especially CFs, is still unclear.

258 Nettelhoff et al. reported that the mRNA expression of RANKL as well as the

259 RANKL/OPG ratio peaked in osteoblasts after 5% CF application by using the Flexcell

260 Compression Plus System [12]. Sanchez et al. also used the Flexcell Compression Plus

261 System, and showed that OPG gene expression was significantly decreased after 4 hours

262 of CF in osteoblasts [22]. Tripuwabhut et al. reported that the application of 4.0 g/cm<sup>2</sup>

263 CF induced significantly increased expression of RANKL mRNA in osteoblasts. They

264 also showed that 2.0 and 4.0 g/cm<sup>2</sup> CF significantly reduced the expression of OPG

265 mRNA [13]. In this study, gene and protein expression levels of RANKL in MLO-Y4

266 and MC3T3-E1 cells reached a maximum 3 hours after applying a CF of 1.0 g/cm<sup>2</sup>. The



267 application of a CF of 1.0 g/cm<sup>2</sup> induced a significant decrease of OPG gene and protein  
268 expressions both in MLO-Y4 and MC3T3-E1 cells. From these findings, both  
269 osteocytes and osteoblasts can respond to CF by upregulating RANKL and  
270 downregulating OPG.

271 Angiogenesis is essential for the development and regeneration of various tissues.  
272 Especially in bone remodeling, bone resorption by osteoclasts and neovascularization  
273 by blood vessel invasion are required for bone morphogenesis and growth. VEGF is a  
274 mitogen specific to vascular endothelial cells and promotes angiogenesis [10]; VEGF  
275 also acts as a vascular permeability factor [23]. Previous studies have shown that  
276 recombinant human VEGF can induce osteoclast generation in osteopetrotic (*op/op*)  
277 mice, which were characterized by a deficiency in osteoclasts, monocytes, and  
278 macrophages due to a lack of functional macrophage-colony stimulating factor  
279 (M-CSF) [24, 25]. It was also demonstrated that local administration of rhVEGF during  
280 experimental tooth movement can increase the number of osteoclasts and accelerate the  
281 rate of tooth movement [26, 27]. Therefore, it is possible that VEGF is closely related to  
282 bone remodeling by inducing osteoclasts as well as angiogenesis. Furthermore,

283 Motokawa et al. reported that cyclic tensile forces enhance the mRNA and protein  
284 expressions of VEGF in MC3T3-E1 cells. Furthermore, Gd<sup>3+</sup> treatment has been  
285 reported to decrease the amount of VEGF mRNA and protein concentration through the  
286 S-A channel [14]. The S-A channel is a membrane stretch-activated ionic channel that  
287 was discovered in tissue-cultured embryonic chick skeletal muscle [28]. It was reported  
288 that stretched cellular membranes increased intracellular Ca<sup>2+</sup> concentration in human  
289 umbilical endothelial cells. The Ca<sup>2+</sup> increase was inhibited by administration of Gd<sup>3+</sup>,  
290 which is a potent blocker for the S-A channel [15]. These findings suggested that cells  
291 can receive mechanical stress mediated by Ca<sup>2+</sup>-permeable S-A channels that exist on  
292 the cell membrane. Additionally, 10 μM Gd<sup>3+</sup> reduced the RANKL and VEGF mRNA  
293 and protein expression levels as well as the RANKL/OPG ratio, which was enhanced by  
294 1.0 g/cm<sup>2</sup> CF application in MLO-Y4 cells. Qin et al. reported that there was a  
295 correlation between the degrees of extension of the cell membrane due to the  
296 application of CF and the activation of the S-A channel [29], suggesting that osteocytes  
297 receive CFs via the S-A channel.  
298 Because the mRNA and protein expression levels of RANKL and VEGF and the

299 RANKL/OPG ratio in MLO-Y4 cells were significantly higher than those in MC3T3-E1  
300 cells in this study, it is possible that osteocytes might play a more important role in bone  
301 metabolism and angiogenesis than osteoblasts, as osteocytes regulate the expression of  
302 RANKL, OPG, and VEGF via the S-A channel by responding to mechanical stress.

303

## 304 **Conclusions**

305 The gene and protein expression of RANKL/OPG ratio and VEGF in MLO-Y4 cells  
306 showed significantly higher than in MC3T3-E1 cells. After CF application, both cells  
307 showed significant increases in RANKL/OPG ratio and VEGF. The upregulated gene  
308 and protein levels of these factors were reduced by Gd<sup>3+</sup> administration.

309

## 310 **Acknowledgment**

311 Editorial support in the form of Medical Writing was provided by Editage.

312

## 313 **References**

314

- 315 1. H Takayanagi. Osteoimmunology: shared mechanisms and crosstalk between the  
316 immune and bone systems. *Nat Rev Immunol.* 2007;7(4):292-304.
- 317 2. T Nakashima, M Hayashi, H Takayanagi. New insights into osteoclastogenic  
318 signaling mechanisms. *Trends Endocrinol. Metab.* 2012;23(11):582-90.
- 319 3. E Seeman, PD Delmas. Bone quality-the material and structural basis of bone  
320 strength and fragility. *N Engl J Med.* 2006;354(21):2250-61.
- 321 4. H Yasuda, N Shima, N Nakagawa. et al. Osteoclast differentiation factor is a ligand  
322 for osteoprotegerin / osteoclastogenesis-inhibitory factor and is identical to  
323 TRANCE/RANKL. *Proc Natl Acad Sci USA.* 1998;95(7):3597-602.
- 324 5. H Yasuda, N Shima, N Nakagawa. et al. Identity of osteoclastogenesis inhibitory  
325 factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF  
326 inhibits osteoclastogenesis in vitro. *Endocrinology.* 1998;139(3):1329-37.
- 327 6. E Jim, I Nakamura, H Amano. et al. Osteoclast function is activated by osteoblastic  
328 cells through a mechanism involving cell-to-cell contact. *Endocrinology.*  
329 1996;137(8):2187-90.
- 330 7. N Udagawa, N Takahashi, E Jimi. et al. Osteoblasts/stromal cells stimulate

- 331 osteoclast activation through expression of osteoclast differentiation factor/RANKL  
332 but not macrophage colony-stimulating factor: receptor activator of NF-kappa B  
333 ligand. *Bone*. 1999;25(5):517-23.
- 334 8. Y Kariya, M Honma, S Aoki. et al. Vps33a mediates RANKL storage in secretory  
335 lysosomes in osteoblastic cells. *J. Bone Miner. Res.* 2009;24(10):1741-52.
- 336 9. S Aoki, M Honma, Y Kariya. et al. Function of OPG as a traffic regulator for  
337 RANKL is crucial for controlled osteoclastogenesis. *J Bone Miner Res.*  
338 2010;25(9):1907-21.
- 339 10. DW Leung, G Cachianes, WJ Kuang. et al. Vascular endothelial growth factor is a  
340 secreted angiogenic mitogen. *Science*. 1989;246(4935):1306-9.
- 341 11. K Hu, BR Olsen. The roles of vascular endothelial growth factor in bone repair and  
342 Regeneration. *Bone*. 2016;91:30-8.
- 343 12. L Nettelhoff, S Grimm, C Jacobs. et al. Influence of mechanical compression on  
344 human periodontal ligament fibroblasts and osteoblasts. *Clin Oral Investig.*  
345 2016;20(3):621-9.
- 346 13. P Tripuwabhrut, M Mustafa, CG Gjerde. et al. Effect of compressive force on

- 347 human osteoblast-like cells and bone remodeling: an in vitro study. Arch Oral Biol.  
348 2013;58(7):826-36.
- 349 14. M Motokawa, M Kaku, Y Tohma. et al. Effects of cyclic tensile forces on the  
350 expression of vascular endothelial growth factor (VEGF) and macrophage-colony  
351 stimulating factor (M-CSF) in murine osteoblastic MC3T3-E1 cells. J Dent Res.  
352 2005;84(5):422-7.
- 353 15. K Naruse, M. Sokabe. Involvement of stretch-activated ion channels in Ca<sup>2+</sup>  
354 mobilization to mechanical stretch in endothelial cells. Am J Physiol.  
355 1993;264(4):1037-44.
- 356 16. P Reher, N Doan, B Bradnock. et al. Effect of ultrasound on the production of IL-8,  
357 basic FGF and VEGF. Cytokine. 1999;11(6):416-23.
- 358 17. LF Bonewald. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229-38.
- 359 18. T Nakashima, M Hayashi, T Fukunaga. et al. Evidence for osteocyte regulation of  
360 bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-34.
- 361 19. J Xiong, M Onal, RL Jilka. et al. Matrix-embedded cells control osteoclast  
362 formation. Nat Med. 2011;17(10):1235-41.

- 363 20. P Tripuwabhrut, K Mustafa, P Brudvik. et al. Initial responses of osteoblasts derived  
364 from human alveolar bone to various compressive force. *Eur J Oral Sci.*  
365 2012;120(4):311-8.
- 366 21. X Yang, F Sachs. Block of stretch-activated ion channels in *Xenopus* oocytes by  
367 gadolinium and calcium ions. *Science.* 1989;243(4894):1068–71.
- 368 22. C Sanchez, O Gabay, C Salvat. et al. Mechanical loading high increases  
369 IL-6production and decreases OPG expression by osteoblasts. *Osteoarthr Cartil.*  
370 2009;17(4):473-81.
- 371 23. DR Senger, SJ Galli, AM Dvorak. et al. Tumor cells secrete a vascular permeability  
372 factor that promotes accumulation of ascites fluid. *Science.* 1983;219(4587):983-5.
- 373 24. S Niida, M Kaku, H Amano. et al. Vascular endothelial growth factor can  
374 substitute for macrophage colony-stimulating factor in the support of osteoclastic  
375 bone resorption. *J Exp Med.* 1999;190(2):293-8.
- 376 25. M Kaku, S Niida, T Kawata. et al. Dose-and time-dependent changes in osteoclast  
377 induction after a single injection of vascular endothelial growth factor in  
378 osteopetrotic mice. *Biomed Res.* 2000;21(2):67-72.

379 26. M Kaku, S Kohno, T Kawata. et al. Effects of vascular endothelial growth factor on

380 osteoclast induction during tooth movement in mice. J Dent Res.

381 2001;80(10):1880-3.

382 27. S Kohno, M Kaku, K Tsutsui. et al. Expression of vascular endothelial growth factor

383 and the effects on bone remodeling during experimental tooth movement. J Dent

384 Res. 2003;82(3):177-82.

385 28. F Guharay, F Sachs. Stretch-activated single ion channel currents in tissue-cultured

386 embryonic skeletal muscle. J Physiol. 1984;352(1):685-701.

387 29. Y Qin, Y Zou, H Hasegawa. et al. Tensile force and (in Japanese), Cardiac

388 Hypertrophy, Vascular Biology and Medicine. 2003;4(3) 229-35.

389






Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E




Figure 2F




Figure 2G






Figure 2H




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 3E




Figure 3F




Figure 3G






Figure 3H




Figure 4A

### VEGF (MC3T3-E1)




Figure 4C

RANKL / OPG(MC3T3-E1)




Figure 4D

### RANKL (MLO-Y4)




Figure 4E




Figure 4F

### VEGF (MLO-Y4)




Figure 4G

### RANKL / OPG (MLO-Y4)




Figure 4H






Figure 5A




Figure 5B




Figure 5C

### RANKL / OPG (MLO-Y4)




Figure 5D




Figure 6A




Figure 6B




Figure 6C




Figure 6D



### OPG (MC3T3-E1)




Figure 4B